Literature DB >> 9546367

Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung.

S Niho1, K Suzuki, T Yokose, T Kodama, Y Nishiwaki, H Esumi.   

Abstract

Sclerosing hemangioma of the lung remains poorly understood, and it is still unclear whether this lesion is neoplastic or not. It consists of two major cell types, pale cells and cuboidal cells. We analyzed the clonality of each cell types from six female cases of surgically resected sclerosing hemangioma. The pale cells and cuboidal cells were separated by microdissection from methanol-fixed sections, and DNA was extracted for clonal analysis based on an X-chromosome-linked polymorphic marker, the human androgen receptor (HUMARA) gene or the phosphoglycerate kinase (PGK) gene. The HUMARA and PGK genes were found to be amplified with or without digestion by the methylation-sensitive restrictive endonuclease HpaII. Five of six cases were informative. Pale cells and cuboidal cells showed the same monoclonality in all of the informative cases, whereas the control cells showed a polyclonal pattern. Our results demonstrated that sclerosing hemangioma is caused by monoclonal expansion of cells, confirming that it is a neoplasia. Moreover, the present data indicate that both pale cells and cuboidal cells are derived from the same cell.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546367      PMCID: PMC1858231     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Sclerosing hemangioma (histiocytoma, xanthoma) of the lung.

Authors:  A A LIEBOW; D S HUBBELL
Journal:  Cancer       Date:  1956 Jan-Feb       Impact factor: 6.860

2.  Clonal origin of human tumors.

Authors:  P J Fialkow
Journal:  Biochim Biophys Acta       Date:  1976-10-12

3.  Electron microscopic study of so-called "pulmonary sclerosing hemangioma". Report of a case suggesting epithelial origin.

Authors:  G S Hill; J C Eggleston
Journal:  Cancer       Date:  1972-10       Impact factor: 6.860

4.  So-called sclerosing hemangioma of the lung. Evidence for mesothelial origin.

Authors:  A L Katzenstein; D L Weise; K Fulling; H Battifora
Journal:  Am J Surg Pathol       Date:  1983-01       Impact factor: 6.394

5.  Benign sclerosing pneumocytoma of lung (sclerosing haemangioma).

Authors:  K W Chan; A R Gibbs; W S Lo; G R Newman
Journal:  Thorax       Date:  1982-06       Impact factor: 9.139

6.  Sclerosing hemangioma of the lung. Immunohistochemical characterization of its origin as related to surfactant apoprotein.

Authors:  N Nagata; M Dairaku; T Ishida; K Sueishi; K Tanaka
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

7.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

8.  Sclerosing hemangioma of the lung: a clinicopathologic study of 51 cases.

Authors:  A L Katzenstein; J T Gmelich; C B Carrington
Journal:  Am J Surg Pathol       Date:  1980-08       Impact factor: 6.394

9.  Sclerosing hemangioma of the lung: an endothelial or epithelial neoplasm?

Authors:  S Kay; W J Still; D Borochovitz
Journal:  Hum Pathol       Date:  1977-07       Impact factor: 3.466

10.  Is sclerosing hemangioma of lung an alveolar mixed tumour?

Authors:  W L Ng; L Ma
Journal:  Pathology       Date:  1983-04       Impact factor: 5.306

View more
  22 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  A case of sclerosing hemangioma of the lung presenting as a gigantic tumor occupying the left thoracic cavity.

Authors:  Rie Shibata; Makio Mukai; Yasunori Okada; Michiie Sakamoto; Tokuko Yamauchi; Koichi Kobayashi
Journal:  Virchows Arch       Date:  2003-03-28       Impact factor: 4.064

Review 3.  ["Pneumocytoma" or "sclerosing hemangioma": histogenetic aspects of a rare tumor of the lung].

Authors:  B M Einsfelder; K-M Müller
Journal:  Pathologe       Date:  2005-09       Impact factor: 1.011

4.  In pulmonary sclerosing hemangioma expression of β-catenin, Axin, and C-myc differs between the two cell types.

Authors:  Xu-Yong Lin; Di Zhang; Yong Zhang; Chui-Feng Fan; Shun-Dong Dai; En-Hua Wang
Journal:  Virchows Arch       Date:  2012-05-22       Impact factor: 4.064

5.  Bilateral multiple sclerosing hemangiomas of the lung.

Authors:  Ryo Maeda; Noritaka Isowa; Hiroshi Miura; Hirokazu Tokuyasu; Yuji Kawasaki; Kazumichi Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-12

6.  Determination of clonal status of pulmonary sclerosing hemangioma with X-chromosome inactivation mosaicism and polymorphism of phosphoglycerate kinase and androgen receptor genes.

Authors:  Li Gong; Kai-Xi Ren; Yan-Hong Li; Xiao-Yan Liu; Wen-Dong Zhang; Li Yao; Shao-Jun Zhu; Xiu-Juan Han; Li Zhang; Miao Lan; Wei Zhang
Journal:  Med Oncol       Date:  2010-04-27       Impact factor: 3.064

7.  Bilateral multiple pulmonary sclerosing hemangioma.

Authors:  Jun Hanaoka; Masatsugu Ohuchi; Shuhei Inoue; Satoru Sawai; Noriaki Tezuka; Shozo Fujino
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-03

8.  Type-II pneumocyte differentiation in pulmonary sclerosing hemangioma: ultrastructural differentiation and immunohistochemical distribution of lineage-specific transcription factors (TTF-1, HNF-3 alpha, and HNF-3 beta) and surfactant proteins.

Authors:  Kazuto Yamazaki
Journal:  Virchows Arch       Date:  2004-05-11       Impact factor: 4.064

9.  A novel, essential control for clonality analysis with human androgen receptor gene polymerase chain reaction.

Authors:  Jeroen P van Dijk; Leonie H Heuver; Bert A van der Reijden; Reinier A Raymakers; Theo de Witte; Joop H Jansen
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

10.  Sixteen cases of sclerosing hemangioma of the lung including unusual presentations.

Authors:  Gou Young Kim; Jhingook Kim; Yong Soo Choi; Ho Joong Kim; Geunghwan Ahn; Joungho Han
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.